BioNTech’s Founders Plan Their Exit as the Company Faces a Pivotal May

BioNTech faces leadership upheaval as founders depart, stock slides 18%, CFO sells shares, and 2026 revenue guidance is cut. Yet oncology pipeline advances with key FDA designations and upcoming data readouts.

The departure of BioNTech’s founding duo, Ugur Sahin and Özlem Türeci, has sent a clear signal to the market: the company is entering a new era, and not everyone is convinced the transition will be smooth. The pair intend to establish a separate mRNA research venture, with a binding agreement on technology transfer expected by the end of June. BioNTech is negotiating a minority stake in the new entity in return.

The announcement of the founder exodus rattled investors in March, with the stock plunging 18% on March 10 to a low of roughly $80. While the shares have since clawed back some ground, they remain under pressure. On Monday, the stock fell nearly 4% to €84.80, extending its weekly decline to over 4%. That puts the gap to the 52-week high of €101.90 at around 17%.

Insider Sale Adds to the Gloom

Compounding the unease, the company’s chief financial officer recently sold shares worth approximately $5.5 million. Insider transactions of this size often pass unnoticed in calmer times, but against the backdrop of a leadership shake-up, the sale has drawn scrutiny from investors already on edge.

BioNTech has also trimmed its 2026 revenue guidance. Management now expects sales in a range of €2.0 billion to €2.3 billion, well below the consensus analyst estimate of €2.75 billion. The cost side of the equation looks equally challenging: the company is pouring billions into oncology research and development, with no cancer-drug revenue expected this year. That leaves the focus squarely on the pace at which BioNTech will burn through its substantial cash pile, which stood at over €17 billion at last count.

Pipeline Progress Offers a Counterpoint

On the operational front, there are bright spots. The antibody-drug conjugate BNT323, targeting HER2-positive uterine cancer, posted strong response rates in a Phase 2 trial. The FDA has granted the candidate both Fast Track and Breakthrough Therapy designations, and BioNTech plans to file for approval later this year.

The broader oncology pipeline is gathering momentum. The company is set to launch six additional Phase 3 studies this year, bringing its total late-stage trials to 15. Seven key data readouts are expected in the coming months, five of which could be pivotal for regulatory submissions. Particular attention is on Phase 3 results for Trastuzumab Pamirtecan, an antibody-drug conjugate developed with Duality Biologics for breast cancer.

Yet not all news is positive. BioNTech and its partner Pfizer are winding down a COVID-19 vaccine trial in the U.S. due to low enrollment, underscoring how sharply interest in pandemic shots has faded.

Geopolitical Headwinds and a Busy Calendar

Adding to the sector-wide uncertainty, potential U.S. tariffs on imported pharmaceuticals are casting a shadow over international biotech companies, BioNTech included.

The immediate test comes on Tuesday, May 5, when BioNTech reports first-quarter results. The earnings call will likely zero in on one question: what does the founders’ departure mean for strategy and R&D priorities? Management’s official commentary will be closely watched for signs of an orderly transition — or further disruption.

The next milestone follows on May 15, when the annual general meeting will vote on expanding the supervisory board from six to eight members, a move tied directly to the succession planning for Sahin and Türeci. With quarterly numbers, the AGM, and a pending spin-off agreement all converging this month, BioNTech’s post-pandemic trajectory is being shaped in real time.